ADAM10 is the main α‐secretase that cleaves APP in the non‐amyloidogenic pathway, thus inhibiting the formation of the β‐amyloid peptide91 Previous studies suggest that AMDM10 exerts neuroprotective effects, and FDA‐approved drugs for AD, such as memantine, can upregulate protein expression and activity of ADAM10, leading to improved cognitive function.92 This evidence concerns the gene APP and Alzheimer disease.